secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2026-05-12T21:24:38+00:00
Accession:  0001034842-26-000038
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel licenses VEPPANU (vepdegestrant) from Arvinas/Pfizer; $70M upfront plus milestones
--------------------------------------------------------------------------------

- Upfront payment of $70M, plus $15M on transition completion; total potential milestones up to $320M.
- Tiered royalties on net sales from mid-teens to mid-twenties percent; sublicense revenue sharing.
- Rigel gets exclusive worldwide rights to develop, manufacture, and commercialize VEPPANU.
- VEPPANU approved in US for ER+/HER2- ESR1-mutated advanced/metastatic breast cancer.
- Deal subject to HSR waiting period expiration or termination.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/0001034842-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000103484226000038/rigl-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001034842-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer